Cerus Corporation Signals Strong Growth in Earnings Call

Cerus Corporation ((CERS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Cerus Corporation’s latest earnings call struck an upbeat tone, with management emphasizing strong commercial momentum and record results despite some margin headwinds. Revenue growth, accelerating IFC demand, and improving profitability metrics dominated the discussion, while executives acknowledged lingering uncertainties around tariffs, R&D funding tapering, and regulatory timelines.

Record Annual Revenue

Cerus reported record total revenue of $233.8 million for 2025, up 16% from 2024 and underscoring sustained adoption of its INTERCEPT platform. Management framed this double‑digit growth as validation of the company’s strategy to deepen penetration in core markets while expanding its therapeutic footprint.

Product Revenue Beat and Growth

Product revenue also hit record levels, rising 14% for both the fourth quarter and full year and beating guidance of $202 million to $204 million. Executives highlighted this outperformance as evidence of robust underlying demand, suggesting that the revenue base is becoming more predictable and diversified.

Strong EMEA Performance

EMEA stood out as a key growth engine, with product revenue excluding FX up 25% in Q4 and 14% for the year, driven by platelet and plasma kit sales and early INT200 uptake. The region’s momentum demonstrates how new product launches and deeper customer engagement can translate into sustained volume expansion.

IFC Demand and Revenue Acceleration

IFC therapeutics continued to ramp, with Q4 product revenue climbing to $4.2 million from $3.0 million a year ago and full‑year sales nearly doubling to $16.7 million. Management stressed that underlying IFC volume grew about 110% year over year, reinforcing the view that the franchise is still in an early, high‑growth phase.

Shift to Kit-Based IFC Model

A strategic shift toward a kit‑based IFC model is reshaping how revenue is recognized, with about 70% of Q4 IFC sales coming from kits versus around 50% last year. Cerus expects nearly all IFC sales to be kit‑based by year‑end, allowing blood centers to scale production while potentially understating near‑term revenue relative to volume growth.

INT200 Regulatory and Commercial Progress

The call spotlighted important INT200 milestones, including CE Mark approval and commercial launch in Europe, where early customer feedback has been positive. Cerus also reiterated its plan to file a U.S. PMA for INT200 around mid‑2026, marking a key step toward expanding its addressable market.

Red Blood Cell Program Milestones

On the red blood cell front, TÜV’s review of the RBC dossier has wrapped up, with the file now moving to France’s ANSM for consultation. In the U.S., the RedeS Phase III trial has completed enrollment, and the company is targeting topline data in late 2026, though it cautioned that regulatory outcomes and timing remain uncertain.

Strategic BCA Agreement

A new group purchasing agreement with Blood Centers of America, effective January 1, was framed as a potential game‑changer for U.S. penetration. With BCA members representing roughly half of the U.S. blood supply and current INTERCEPT penetration around 30% within the group, Cerus sees opportunity for broader adoption and simplified contracting.

Profitability and Cash Position

Cerus posted its seventh consecutive quarter of positive adjusted EBITDA at $3.4 million and its second straight positive year at $9.5 million, while narrowing its GAAP net loss to $15.6 million. The company ended 2025 with about $83 million in cash and short‑term investments, supported by $4.8 million in operating cash flow for the year.

2026 Revenue Guidance and IFC Outlook

Management reaffirmed 2026 product revenue guidance of $224 million to $228 million, implying 9% to 11% growth, including IFC revenue of $20 million to $22 million, or roughly 20% to 30% growth. Executives also signaled confidence in delivering another year of positive adjusted EBITDA as IFC scales and the broader portfolio matures.

Commercial Momentum in Key Markets

Germany emerged as a notable opportunity, with the INITIATE Phase IV study underway and an estimated platelet market potential of about $30 million annually. Cerus also reported traction in Middle Eastern markets such as Saudi Arabia, Kuwait, and Qatar, while acknowledging that regional geopolitical dynamics could affect adoption timing.

Product Gross Margin Compression

Despite revenue strength, product gross margins slipped to 51.5% in Q4 from 53.9% a year earlier, a roughly 2.4‑point decline. Management attributed the pressure to higher IFC production costs, import tariffs, and broader inflation, signaling that profitability gains may be uneven quarter to quarter.

Tariff and Inflation Uncertainty

Tariffs and inflation remain wild cards for future margins, with the company unable to forecast the ultimate impact on 2026 gross profit. While Cerus expects margins to hover in the low‑50% range, it warned investors to anticipate variability as these macro factors evolve.

GAAP Loss Remains

Cerus is edging closer to break‑even but still posted a GAAP net loss of $15.6 million for the year and $2.2 million in Q4. Management framed the narrowing loss as progress toward full profitability, supported by recurring EBITDA positivity and disciplined cash management.

R&D Reimbursement and Revenue Taper Risk

The company highlighted that BARDA‑related reimbursed R&D revenue was materially elevated in 2025 but is set to taper as the contract expires in September. This expected decline in high‑margin reimbursed revenue could weigh on top‑line growth optics in 2026, even as core product sales expand.

Revenue Recognition vs. Underlying IFC Demand

Executives emphasized that reported IFC revenue growth of about 80% understates the true demand picture, given volumes surged roughly 110%. As the business mix shifts from finished therapeutics to blood‑center kits, the financial statements may lag actual usage trends, complicating near‑term comparisons.

Operating Expense Increases

Operating expenses rose 7% in Q4 and 10% for the full year as Cerus continued to invest behind growth, particularly in commercialization and R&D. Management acknowledged that if revenue growth slows, these higher costs could limit operating leverage and delay the path to GAAP profitability.

Regulatory and Timing Uncertainties

The company reiterated that RBC CE approval timing depends on ANSM’s review process, currently estimated around a 210‑day clock, implying potential approval in the first half of 2027 if all goes smoothly. Combined with U.S. RedeS data expected in late 2026, these timelines introduce a layer of regulatory and execution risk into the long‑term story.

Geopolitical and Market Flux in Middle East

While Cerus sees promising growth in markets like Saudi Arabia, it cautioned that geopolitical developments in the Middle East are creating market flux that could affect rollout pacing. Investors were reminded that international expansion, while attractive, comes with additional volatility and timing uncertainty.

Outlook and Forward-Looking Guidance

Looking ahead, Cerus expects 2026 product revenue of $224 million to $228 million, IFC sales of $20 million to $22 million, and product gross margins in the low‑50% range. Management is targeting a third straight year of positive adjusted EBITDA, continued operating cash flow, and further progress toward GAAP profitability, even as tariffs and inflation may cause quarterly margin swings.

Cerus’s earnings call painted the picture of a company growing into its global opportunity, supported by record sales, accelerating IFC demand, and improving profitability trends. While investors must weigh margin pressures, R&D funding tapering, and regulatory and geopolitical uncertainties, management’s reaffirmed guidance and strategic milestones suggest the growth story remains intact.